By the end of this video, you will be
able to list safety factors involved in determining appropriate doses for
a molecule as it enters clinical trials. You will also be able to
define some of the common terminology used with
early dose selection. This slide shows a typical phase I. Clinical study dose range for
small molecule drugs, this dose range will begin at or below the maximum recommended
starting dose or MRSD. The MRSD is a dose determined
from preclinical toxicology and PK data and expected to be safe. The MRSD is a low enough dose or
exposure that no adverse effects are expected in test subjects and
no therapeutic effect is likely. Once the compound is confirmed
to be safe at a low dose, gradual dose escalation will
occur in additional subjects. These higher doses may exceed
the predicted human efficacious dose, both to fully investigate the human PK and
determine to what extent the dose can be increased until unacceptable
tolerability or adverse events occur. For most indications other than cancer,
the focus of these phase I trials is to investigate safety, tolerability,
and PK, but not efficacy. The MRSD, maximum recommended
starting dose is a key value for starting clinical trials. An MRSD can be determined in several ways,
the most common being through use of the No Observed
Adverse Effect Level, NOAEL. The NOAEL is the highest dose of
a molecule that does not cause adverse effects during preclinical toxicology or
safety studies. It is also important to understand
whether the MRSD is anticipated to elicit a clinically relevant or
pharmacodynamic response in a human, particularly in general medicine where the
phase I subjects are healthy volunteers. Regulatory agencies provide additional
guidelines for further lowering the starting dose to minimize the risk of
encountering unanticipated adverse events. The NOAEL is also used to determine
the maximum dose in humans, particularly in general medicine trials. However, rather than using the NOAEL dose
from the preclinical toxicology studies, the NOAEL exposure is used to
calculate a human dose equivalent. This exposure cap, as it may be called,
cannot be exceeded in a first in human trial without sound scientific and
clinical justification. An example of such justification
might be that any anticipated adverse events are minor, reversible, or
easily monitored in the clinic. Calculation of an exposure cap alone
does not justify dose escalation to that level in healthy volunteers,
particularly if the exposure cap exceeds the anticipated human
therapeutic dose range. First-in-human trials for
oncology indications or in some cases fatal disease where
there is no therapeutic alternative, are designed differently from
most other first-in-human trials. While phase I trials typically
involve healthy volunteers, in oncology trials,
phase I subjects are cancer patients. This is because molecules used against
cancer targets often have significant safety risks beyond those seen in
molecules for other indications. Therefore, the testing of potential cancer
drugs in healthy subjects would not be ethical. Another difference for phase I oncology
trials is the MRSD is not calculated based on the NOAEL and is expected
to have some therapeutic effect. Because trial subjects have cancer,
it is considered unethical to use a dose of the drug not expected to
provide some benefit to the patient. Finally, oncology studies
are typically not limited by a pre-determined exposure cap. Dose escalations continue until some
number of patients in a dose group experience what are referred to
as dose limiting toxicities. This approach is acceptable to identify
a maximally efficacious dose that, while perhaps having
significant safety risks, will be accepted by cancer patients
in return for the clinical benefit. Preclinical safety studies
are critical not only for understanding the potential safety
risks of a drug, but also for determining both the starting and
maximum doses for human clinical studies.